Treatment of Viral Infections in Immunocompromised Patients Using Third Party Viral Specific T-cells VSTs

What this Trial Is About

This research aims to demonstrate that viral specific T-cells VSTs, a type of white blood cell, can be safely produced from unrelated donors and given to immunocompromised patients with viral infections. The study focuses on patients including those who have received stem cell transplants and are experiencing viral reactivation or infection from viruses such as Epstein-Barr virus EBV, cytomegalovirus CMV, adenovirus ADV, BK virus BKV, and JC virus. These infections are a major cause of illness in immunocompromised individuals. VSTs are created by drawing blood from unrelated donors and selecting cells specific to the recipients viral infection and HLA type. The selected VSTs are then infused into the patient. This is an interventional study where the infusion is given to children and other immunocompromised patients with evidence of viral infection or reactivation. The study includes monitoring for infusion reactions and graft versus host disease GVHD. Participants will be monitored for successful production of VSTs within 30 days of culture initiation, infusion reactions within 30 minutes after the infusion, and the incidence of GVHD within 30 days post-infusion. Researchers will also assess the presence of viral-specific T-cells and viral load at 30 days after infusion. The study requires participants to be able to receive the infusion at the study location and involves informed consent procedures. The study continues through to December 2027.

Third Party Viral Specific T-cells (VSTs)